CL2012002541A1 - Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros. - Google Patents
Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.Info
- Publication number
- CL2012002541A1 CL2012002541A1 CL2012002541A CL2012002541A CL2012002541A1 CL 2012002541 A1 CL2012002541 A1 CL 2012002541A1 CL 2012002541 A CL2012002541 A CL 2012002541A CL 2012002541 A CL2012002541 A CL 2012002541A CL 2012002541 A1 CL2012002541 A1 CL 2012002541A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- schizophrenia
- anxiety
- stress
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuesto cristalino hidrato del hidrobromuro de agomelatina; método de preparación del compuesto; composición farmacéutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresión mayor, esquizofrenia, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101262639A CN102190595A (zh) | 2010-03-17 | 2010-03-17 | 阿戈美拉汀溴化氢水合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012002541A1 true CL2012002541A1 (es) | 2013-01-11 |
Family
ID=44599557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012002541A CL2012002541A1 (es) | 2010-03-17 | 2012-09-13 | Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros. |
Country Status (39)
Country | Link |
---|---|
US (1) | US8729132B2 (es) |
EP (1) | EP2547650B1 (es) |
JP (1) | JP5634533B2 (es) |
KR (1) | KR101406736B1 (es) |
CN (2) | CN102190595A (es) |
AP (1) | AP3199A (es) |
AU (1) | AU2011229619B2 (es) |
BR (1) | BR112012023173B1 (es) |
CA (1) | CA2792430C (es) |
CL (1) | CL2012002541A1 (es) |
CR (1) | CR20120461A (es) |
CU (1) | CU20120136A7 (es) |
CY (1) | CY1117134T1 (es) |
DK (1) | DK2547650T3 (es) |
EA (1) | EA022066B1 (es) |
EC (1) | ECSP12012156A (es) |
ES (1) | ES2572427T3 (es) |
GE (1) | GEP20156232B (es) |
GT (1) | GT201200260A (es) |
HK (1) | HK1177732A1 (es) |
HN (1) | HN2012001923A (es) |
HR (1) | HRP20151343T1 (es) |
HU (1) | HUE026673T2 (es) |
IL (1) | IL221783A (es) |
MA (1) | MA34054B1 (es) |
ME (1) | ME02309B (es) |
MX (1) | MX2012010594A (es) |
MY (1) | MY160337A (es) |
NI (1) | NI201200141A (es) |
NZ (1) | NZ602451A (es) |
PE (1) | PE20130014A1 (es) |
PL (1) | PL2547650T3 (es) |
PT (1) | PT2547650E (es) |
RS (1) | RS54449B1 (es) |
SG (1) | SG183869A1 (es) |
SI (1) | SI2547650T1 (es) |
TN (1) | TN2012000436A1 (es) |
UA (1) | UA105424C2 (es) |
WO (1) | WO2011113363A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
CN102718675B (zh) * | 2012-06-07 | 2015-03-25 | 上海右手医药科技开发有限公司 | 阿戈美拉汀甲磺酸复合物及其制备方法 |
WO2013170738A1 (zh) * | 2012-05-14 | 2013-11-21 | 上海右手医药科技开发有限公司 | 阿戈美拉汀酸根复合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
CN1498216A (zh) * | 2000-10-30 | 2004-05-19 | ������ҩ��ҵ����˾ | 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法 |
FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
CN101585779B (zh) | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
-
2010
- 2010-03-17 CN CN2010101262639A patent/CN102190595A/zh active Pending
-
2011
- 2011-03-17 BR BR112012023173-1A patent/BR112012023173B1/pt not_active IP Right Cessation
- 2011-03-17 GE GEAP201112870A patent/GEP20156232B/en unknown
- 2011-03-17 EP EP11755680.3A patent/EP2547650B1/en active Active
- 2011-03-17 PL PL11755680T patent/PL2547650T3/pl unknown
- 2011-03-17 MX MX2012010594A patent/MX2012010594A/es active IP Right Grant
- 2011-03-17 KR KR1020127026897A patent/KR101406736B1/ko active IP Right Grant
- 2011-03-17 JP JP2012557393A patent/JP5634533B2/ja not_active Expired - Fee Related
- 2011-03-17 AU AU2011229619A patent/AU2011229619B2/en not_active Ceased
- 2011-03-17 NZ NZ602451A patent/NZ602451A/en not_active IP Right Cessation
- 2011-03-17 UA UAA201211719A patent/UA105424C2/uk unknown
- 2011-03-17 DK DK11755680.3T patent/DK2547650T3/en active
- 2011-03-17 CA CA2792430A patent/CA2792430C/en active Active
- 2011-03-17 SI SI201130723T patent/SI2547650T1/sl unknown
- 2011-03-17 MA MA35191A patent/MA34054B1/fr unknown
- 2011-03-17 AP AP2012006493A patent/AP3199A/xx active
- 2011-03-17 ME MEP-2016-9A patent/ME02309B/me unknown
- 2011-03-17 US US13/635,087 patent/US8729132B2/en active Active
- 2011-03-17 SG SG2012065017A patent/SG183869A1/en unknown
- 2011-03-17 EA EA201201293A patent/EA022066B1/ru unknown
- 2011-03-17 WO PCT/CN2011/071912 patent/WO2011113363A1/en active Application Filing
- 2011-03-17 MY MYPI2012700614A patent/MY160337A/en unknown
- 2011-03-17 HU HUE11755680A patent/HUE026673T2/en unknown
- 2011-03-17 CN CN201180024413.8A patent/CN102892749B/zh not_active Expired - Fee Related
- 2011-03-17 PT PT117556803T patent/PT2547650E/pt unknown
- 2011-03-17 ES ES11755680T patent/ES2572427T3/es active Active
- 2011-03-17 PE PE2012001449A patent/PE20130014A1/es active IP Right Grant
- 2011-03-17 RS RS20150831A patent/RS54449B1/en unknown
-
2012
- 2012-08-31 TN TNP2012000436A patent/TN2012000436A1/en unknown
- 2012-09-04 IL IL221783A patent/IL221783A/en not_active IP Right Cessation
- 2012-09-11 CR CR20120461A patent/CR20120461A/es unknown
- 2012-09-12 NI NI201200141A patent/NI201200141A/es unknown
- 2012-09-13 CL CL2012002541A patent/CL2012002541A1/es unknown
- 2012-09-14 EC ECSP12012156 patent/ECSP12012156A/es unknown
- 2012-09-14 HN HN2012001923A patent/HN2012001923A/es unknown
- 2012-09-17 CU CU2012000136A patent/CU20120136A7/es unknown
- 2012-09-17 GT GT201200260A patent/GT201200260A/es unknown
-
2013
- 2013-04-23 HK HK13104895.3A patent/HK1177732A1/xx not_active IP Right Cessation
-
2015
- 2015-12-08 HR HRP20151343TT patent/HRP20151343T1/hr unknown
-
2016
- 2016-01-18 CY CY20161100041T patent/CY1117134T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
NI201400070A (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido. | |
CO6940374A2 (es) | Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
IN2014DN09434A (es) | ||
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
ECSP13012958A (es) | Inhibidores de benzodioxano de la producción de leucotrieno. | |
CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
CR20200220A (es) | FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222) | |
ECSP12012270A (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
CL2011002231A1 (es) | Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo. | |
AR086586A1 (es) | Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma | |
BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
CL2011001405A1 (es) | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. | |
BRPI0915428A2 (pt) | derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios | |
DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
GT201100300A (es) | Piperidinas sustituidas |